Will the Oxford Biomedica share price keep on climbing?

The Oxford Biomedica share price is surging after extending its deal with AstraZeneca. Zaven Boyrazian investigates if this momentum can continue.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

The Oxford Biomedica (LSE:OXB) share price reached its highest point in over a decade this month. Like many other biotech companies, the group quickly shifted its focus to help tackle the worsening pandemic. And consequently, the firm landed one of its most lucrative partnerships to date – the manufacture of AstraZeneca’s Covid-19 vaccine.

This deal seems to have been one of the primary drivers behind Oxford Biomedica’s rapidly rising share price in 2020 that helped push it from 673p to 1,000p by the end of the year. This growth has continued since, and over the last 12 months, the stock is up more than 60%. But is this momentum about to accelerate?

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Guidance gets vaccinated

I’ve previously explored Oxford Biomedica and its partnership with AstraZeneca. But as a quick reminder, the company is a small biotech group that has developed a proprietary drug development platform called LentiVector. This technology is ultimately what landed it with an 18-month vaccine manufacturing deal with AstraZeneca as it significantly reduces the hefty development costs of new medicines.

The original contract was expected to generate around £50m of additional revenue for the business. However, last month, the management team made an announcement that saw the Oxford Biomedica share price jump by double-digits within a day. Following the successful production achievements so far, AstraZeneca has agreed to increase the number of vaccine batches that Oxford Biomedica must deliver in the second half of 2021. In other words, the order sizes, and therefore income, from this deal just increased.

It’s not clear as to the exact value of the income this newly reformed agreement will generate. However, revenue guidance was raised from £50m to over £100m from this contract alone. Combining this with the income being generated from the vast collection of other products being developed on LentiVector, I believe 2021 will be a transformative year for Oxford Biomedica and its share price.

The Oxford Biomedica share price has its risks

As promising as this progress is, there are still several risks that this business faces. The most prominent of which is long-term revenue generation. The deal signed with AstraZeneca has a maximum term period of three years. In other words, it may not be a sustainable source of long-term income. This is particularly troubling given how dominant this partnership has become in the overall revenue stream for Oxford Biomedica.

The cash flows generated from this deal certainly provide a large amount of capital for reinvestment. Improvements to LentiVector may, in turn, attract additional customers that can replace the eventual loss of revenue. However, whether this can be achieved before its vaccine contract expires remains to be seen.

Needless to say, if investors see a sudden decline in Oxford Biomedica’s gross income, then I think the share price could begin to experience some significant volatility. After all, it looks like a lot of the firm’s valuation is being driven by future expectations.

The Oxford Biomedica share price has its risks

The bottom line

I’ve been an investor in Oxford Biomedica for several years now. My original investment thesis surrounded the potential of the LentiVector platform. Personally, I still believe that potential remains substantial, even after the AstraZeneca contract expires. Therefore, despite the risks, I’m cautiously optimistic that the Oxford Biomedica share price will continue to climb over the long term.

But it's not the only growth stock I have my eye on...

One FTSE “Snowball Stock” With Runaway Revenues

Looking for new share ideas?

Grab this FREE report now.

Inside, you discover one FTSE company with a runaway snowball of profits.

From 2015-2019…

  • Revenues increased 38.6%.
  • Its net income went up 19.7 times!
  • Since 2012, revenues from regular users have almost DOUBLED

The opportunity here really is astounding.

In fact, one of its own board members recently snapped up 25,000 shares using their own money...

So why sit on the side lines a minute longer?

You could have the full details on this company right now.

Grab your free report – while it’s online.

Zaven Boyrazian owns shares in Oxford Biomedica. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Happy retired couple on a yacht
Investing Articles

This growth stock has seen its shares pull back! Should I buy now?

When a growth stock sees its share price drop, I look carefully to see if I could pick up a…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

How to identify the best income shares like this one

Income shares vary in quality but this approach keeps me from making some of the worst howlers with dividend investing.

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Investing Articles

If I’d invested £1k in Tesla shares a year ago, here’s how much I’d have now

If Jon Smith had bought Tesla shares a year ago, he'd be in profit. But he has some concerns for…

Read more »

Twenty pound notes in back pocket of jeans
Investing Articles

Should I buy tobacco shares now for big dividends?

After a possible setback for electronic cigarettes, our writer explains why he would still buy tobacco shares for his income…

Read more »

a couple embrace in front of their new home
Investing Articles

3 FTSE shares I’m buying with the Help to Build scheme!

Last week, the government launched a new, Help to Build scheme. So, here are three FTSE shares that could benefit…

Read more »

Stack of one pound coins falling over
Investing Articles

Should I bite on these 4 double-digit dividends?

Our writer considers whether these four double-digit dividends look sustainable and what that means for his portfolio.

Read more »

Close-up of British bank notes
Investing Articles

Can the Rolls-Royce share price get any cheaper than 80p?

The Rolls-Royce share price was edging back towards £1 and maybe above penny share levels. But then new troubles sent…

Read more »

Senior woman wearing glasses using laptop at home
Investing Articles

2 value stocks with high dividend yields to buy in July

Our writer examines two value stocks for his portfolio that marry low price-to-earnings ratios with high dividend yields.

Read more »